Advanced Waldenström's macroglobulinemia: Usefulness of Morel's scoring system in establishing prognosis

Haematologica

Volumn 90, Issue 2, 2005, Pages 279-281

  Lévy, Vincent ^a,b   Morel, Pierre ^c   Porcher, Raphaël ^a,b   Chevret, Sylvie ^b,d   Wattel, Eric ^a   Leblond, Véronique ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c Hopital Schaffner   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Fludarabine; Prognostic factors; Waldenstr m's macroglobulinemia

Indexed keywords

ALKYLATING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LACTATE DEHYDROGENASE; PREDNISONE;

AGED; ARTICLE; BONE MARROW BIOPSY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATOMEGALY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHADENOPATHY; MACROGLOBULINEMIA; MAJOR CLINICAL STUDY; MALE; MOREL SCORING SYSTEM; MULTICENTER STUDY; MYELOFIBROSIS; PERTHES DISEASE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; SPLENOMEGALY; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; TIME FACTORS; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 14344258162     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214-26.
2. Foran JM, Rohatiner AZ, Coiffier B, Barbui T, Johnson SA, Hiddemann W, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999;17:546-53.
3. Leblond V, Levy V, Maloisel F, Cazin B, Fermand JP, Remenieras JJ, et al. Results of a multicentric randomized study comparing the efficacy of fludarabine to that of cyclophosphamide, doxorubicine and prednisone in 92 patients with Waldenström's macroglobulinemia in first relapse or primary refractory disease. Blood 2001;98:2640-4.
4. Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström's macroglobulinemia: results of united States intergroup trial (Southwest Oncology Group S9003). Blood 2001;98:41-8.
5. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, et al. Patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852-8.
6. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958;35:457-81
7. Cox D. Regression models and life tables. J R Statist Soc B 1972;34:187-201.
8. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residual. Biometrika 1994;81: 515-26.
9. Hurvich CM, Tsai CL. Regression and time series model selection in small samples. Biometrika 1989;76:297-307.
10. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-73.